SCHEMBL6073499

SCHEMBL6073499

O=C(Nc1nc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2cc1Br)NC1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 16/20 0.55
CCND1 P24385 15/20 0.55
CDK2 P24941 12/20 0.55
CCNA2 P20248 11/20 0.55
FGFR1 P11362 11/20 0.55
FGFR2 P21802 11/20 0.55
FGFR4 P22455 11/20 0.55
FGFR3 P22607 11/20 0.55
CCND2 P30279 4/20 0.55
CCND3 P30281 4/20 0.55
CCNA1 P78396 3/20 0.55
SYK P43405 2/20 0.53
IGF1R P08069 1/20 0.49
CCNE1 P24864 3/20 0.49
CDK1 P06493 2/20 0.49
CCNB1 P14635 2/20 0.49
CCNE2 O96020 2/20 0.48
TNK2 Q07912 1/20 0.47
CDK6 Q00534 1/20 0.46
CCNB2 O95067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073818 0.91 CDK4 (0.55) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6074793 0.90 SYK (0.53) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073707 0.90 CDK4 (0.55) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073628 0.88 SYK (0.51) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073608 0.87 CDK4 (0.48) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073614 0.87 CDK4 (0.48) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073793 0.86 CDK4 (0.51) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6074210 0.85 CDK4 (0.58) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6074226 0.85 CDK4 (0.54) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL6073956 0.85 CCND3 (0.53) CDK4CCND1CDK2CCNA2CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CDK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.